Trial tests aggressive stem cell treatment for rare blood cancer
NCT ID NCT02844361
Summary
This study aimed to see if a patient's own stem cells, collected and transplanted back after high-dose chemotherapy, works better than standard chemotherapy alone for people with high-risk Waldenström macroglobulinemia, a rare blood cancer. It involved 70 patients in China who had responded partially to initial treatment. The main goal was to compare how long patients lived without their cancer getting worse between the two treatment approaches.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTRÖM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shuhua Yi
Tianjin, 300020, China
Conditions
Explore the condition pages connected to this study.